Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway and Their Relationship with High Blood Pressure Risk
Metadatos
Mostrar el registro completo del ítemAutor
Rojo Tolosa, Susana; Márquez Pete, Noelia; Gálvez Navas, José María; Pineda Lancheros, Laura Elena; Fernández Alonso, Andrea; Membrive Jiménez, Cristina; Ramírez Tortosa, María Carmen; Pérez Ramírez, Cristina; Jiménez Morales, AlbertoEditorial
MDPI
Materia
High blood pressure Vitamin D Risk Genetic polymorphisms CYP2R1 CYP27B1 CYP24A1 GC VDR
Fecha
2023-03-22Referencia bibliográfica
Rojo-Tolosa, S.; Márquez-Pete, N.; Gálvez-Navas, J.M.; Pineda-Lancheros, L.E.; Fernández-Alonso, A.; Membrive-Jiménez, C.; Ramírez-Tortosa, M.C.; Pérez-Ramírez, C.; Jiménez-Morales, A. Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway and Their Relationship with High Blood Pressure Risk. Int. J. Mol. Sci. 2023, 24, 5974. [https://doi.org/10.3390/ijms24065974]
Patrocinador
ERDF funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039) supported by co-funding grants from the Biobank of the Hospital Universitario Virgen de las Nieves.Resumen
High blood pressure (HBP) is the leading risk factor for cardiovascular disease (CVD) and
all-cause mortality worldwide. The progression of the disease leads to structural and/or functional
alterations in various organs and increases cardiovascular risk. Currently, there are significant
deficiencies in its diagnosis, treatment, and control. Vitamin D is characterized by its functional
versatility and its involvement in countless physiological processes. This has led to the association
of vitamin D with many chronic diseases, including HBP and CVD, due to its involvement in the
regulation of the renin–angiotensin–aldosterone system. The aim of this study was to evaluate the
effect of 13 single nucleotide polymorphisms (SNPs) related to the vitamin D metabolic pathway
on the risk of developing HBP. An observational case-control study was performed, including
250 patients diagnosed with HBP and 500 controls from the south of Spain (Caucasians). Genetic
polymorphisms in CYP27B1 (rs4646536, rs3782130, rs703842, and rs10877012), CYP2R1 rs10741657,
GC rs7041, CYP24A1 (rs6068816, and rs4809957), and VDR (BsmI, Cdx2, FokI, ApaI, and TaqI) were
analyzed by real-time PCR using TaqMan probes. Logistic regression analysis, adjusted for body
mass index (BMI), dyslipidemia, and diabetes, showed that in the genotypic model, carriers of the
GC rs7041 TT genotype were associated with a lower risk of developing HBP than the GG genotype
(odds ratio (OR) = 0.44, 95% confidence interval (CI): 0.41–0.77, p = 0.005, TT vs. GG). In the dominant
model, this association was maintained; carriers of the T allele showed a lower risk of developing
HBP than carriers of the GG genotype (OR = 0.69, 95% CI: 0.47–1.03; TT + TG vs. GG, p = 0.010).
Finally, in the additive model, consistent with previous models, the T allele was associated with a
lower risk of developing HBP than the G allele (OR = 0.65, 95% CI: 0.40–0.87, p = 0.003, T vs. G).
Haplotype analysis revealed that GACATG haplotypes for SNPs rs1544410, rs7975232, rs731236,
rs4646536, rs703842, and rs10877012 were associated with a marginally significant lower risk of
developing HBP (OR = 0.35, 95% CI: 0.12–1.02, p = 0.054). Several studies suggest that GC 7041 is
associated with a lower active isoform of the vitamin D binding protein. In conclusion, the rs7041
polymorphism located in the GC gene was significantly associated with a lower risk of developing
HBP. This polymorphism could therefore act as a substantial predictive biomarker of the disease.